Michael Hofman, Nuclear Medicine Physician at Melbourne’s Peter MacCallum Cancer Centre, shared a post on X/Twitter:
”Oliver Sartor presenting PSMAfore at SNMMI.
All efficacy endpoints favour Lu-PSMA617: better efficacy, quality of life, less side effects. Except, no difference in overall survival.”
Source: Michael Hofman/X
